Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$2.41 USD
-0.02 (-0.82%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.41 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CKPT 2.41 -0.02(-0.82%)
Will CKPT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CKPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CKPT
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
CKPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CKPT
Buy Rating Justified by Promising Efficacy of Checkpoint’s Cosibelimab in Clinical Trials
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Checkpoint Therapeutics announces presentation of data on cosibelimab
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success